Company / Shareholders' Equity
Oncology Institute, Inc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$3.6M
FY2025
5-year range
$3.6M / $123.2M
FY2021-FY2025
Trend
-93.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $123M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2025 with a 3-year CAGR of -67.5%.
Declined from $123M to $4M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -67.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -67.5%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 93.7% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.6M | -93.7% |
| FY2024 | $57.0M | -53.7% |
| FY2023 | $123.2M | +18.3% |
| FY2022 | $104.2M | +270.7% |
| FY2021 | $28.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026